TW200509944A - Metabolite - Google Patents
MetaboliteInfo
- Publication number
- TW200509944A TW200509944A TW093120058A TW93120058A TW200509944A TW 200509944 A TW200509944 A TW 200509944A TW 093120058 A TW093120058 A TW 093120058A TW 93120058 A TW93120058 A TW 93120058A TW 200509944 A TW200509944 A TW 200509944A
- Authority
- TW
- Taiwan
- Prior art keywords
- quetiapine fumarate
- antipsychotic
- side effects
- fewer
- quetiapine
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title abstract 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 abstract 8
- 229960005197 quetiapine fumarate Drugs 0.000 abstract 6
- 230000000694 effects Effects 0.000 abstract 4
- 230000000561 anti-psychotic effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010002942 Apathy Diseases 0.000 abstract 1
- 206010012239 Delusion Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 206010014557 Emotional poverty Diseases 0.000 abstract 1
- 208000004547 Hallucinations Diseases 0.000 abstract 1
- 206010020400 Hostility Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- JLOAJISUHPIQOX-UHFFFAOYSA-N Norquetiapine Chemical compound C1CNCCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 JLOAJISUHPIQOX-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 229940124604 anti-psychotic medication Drugs 0.000 abstract 1
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000868 delusion Toxicity 0.000 abstract 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009509 drug development Methods 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940035004 seroquel Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436503P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200509944A true TW200509944A (en) | 2005-03-16 |
Family
ID=33563981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093120058A TW200509944A (en) | 2003-07-02 | 2004-07-02 | Metabolite |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050026900A1 (https=) |
| EP (1) | EP1644005B1 (https=) |
| JP (1) | JP2007516193A (https=) |
| KR (1) | KR20060082037A (https=) |
| CN (1) | CN1816339B (https=) |
| AR (1) | AR045004A1 (https=) |
| AT (1) | ATE477803T1 (https=) |
| AU (1) | AU2004253334A1 (https=) |
| BR (1) | BRPI0412127A (https=) |
| CA (1) | CA2531284A1 (https=) |
| DE (1) | DE602004028739D1 (https=) |
| ES (1) | ES2349091T3 (https=) |
| IL (1) | IL172616A0 (https=) |
| IS (1) | IS8283A (https=) |
| MX (1) | MXPA05013869A (https=) |
| NO (1) | NO20060556L (https=) |
| RU (1) | RU2005141060A (https=) |
| TW (1) | TW200509944A (https=) |
| UY (1) | UY28400A1 (https=) |
| WO (1) | WO2005002586A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL164155A0 (en) * | 2002-03-20 | 2005-12-18 | Teva Pharma | Crystalline forms of quetiapine hemifumarate |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| PT1696931E (pt) | 2003-12-22 | 2009-06-12 | Acadia Pharm Inc | Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
| AU2006231497A1 (en) * | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
| US7687622B2 (en) * | 2005-04-14 | 2010-03-30 | Teva Pharmaceutical Industries, Ltd | Process for preparing quetiapine fumarate |
| WO2007004234A1 (en) * | 2005-07-04 | 2007-01-11 | Usv Limited | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE |
| WO2008079848A1 (en) * | 2006-12-20 | 2008-07-03 | Astrazeneca Ab (Se/Se) | Compounds and uses thereof |
| WO2007062337A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Crystalline forms |
| WO2007062339A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| WO2008116144A1 (en) * | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Methods of treating mood disorders |
| JP2009516705A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 塩の形態 |
| US8389510B2 (en) | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| WO2007062338A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| JP2010531292A (ja) * | 2006-12-20 | 2010-09-24 | アストラゼネカ・アクチエボラーグ | 化合物及びその使用 |
| EP2120563A4 (en) * | 2006-12-20 | 2011-04-27 | Astrazeneca Ab | CONNECTIONS AND ITS USES |
| US8715699B2 (en) | 2009-12-31 | 2014-05-06 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| WO2011112657A1 (en) | 2010-03-11 | 2011-09-15 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| CN102552128B (zh) * | 2012-02-28 | 2013-09-18 | 陆荣政 | 一种富马酸喹硫平注射液及其制备方法 |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| WO2000010572A1 (en) * | 1998-08-18 | 2000-03-02 | Sepracor Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
-
2004
- 2004-06-28 KR KR1020057025264A patent/KR20060082037A/ko not_active Withdrawn
- 2004-06-28 CA CA002531284A patent/CA2531284A1/en not_active Abandoned
- 2004-06-28 ES ES04743131T patent/ES2349091T3/es not_active Expired - Lifetime
- 2004-06-28 WO PCT/GB2004/002783 patent/WO2005002586A1/en not_active Ceased
- 2004-06-28 JP JP2006518324A patent/JP2007516193A/ja not_active Ceased
- 2004-06-28 BR BRPI0412127-9A patent/BRPI0412127A/pt not_active IP Right Cessation
- 2004-06-28 AT AT04743131T patent/ATE477803T1/de not_active IP Right Cessation
- 2004-06-28 DE DE602004028739T patent/DE602004028739D1/de not_active Expired - Lifetime
- 2004-06-28 EP EP04743131A patent/EP1644005B1/en not_active Expired - Lifetime
- 2004-06-28 AU AU2004253334A patent/AU2004253334A1/en not_active Abandoned
- 2004-06-28 CN CN2004800188710A patent/CN1816339B/zh not_active Expired - Fee Related
- 2004-06-28 RU RU2005141060/15A patent/RU2005141060A/ru not_active Application Discontinuation
- 2004-06-28 MX MXPA05013869A patent/MXPA05013869A/es not_active Application Discontinuation
- 2004-07-01 US US10/883,024 patent/US20050026900A1/en not_active Abandoned
- 2004-07-02 UY UY28400A patent/UY28400A1/es not_active Application Discontinuation
- 2004-07-02 AR ARP040102345A patent/AR045004A1/es not_active Application Discontinuation
- 2004-07-02 TW TW093120058A patent/TW200509944A/zh unknown
-
2005
- 2005-12-15 IL IL172616A patent/IL172616A0/en unknown
-
2006
- 2006-02-01 IS IS8283A patent/IS8283A/is unknown
- 2006-02-02 NO NO20060556A patent/NO20060556L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050026900A1 (en) | 2005-02-03 |
| CA2531284A1 (en) | 2005-01-13 |
| NO20060556L (no) | 2006-04-03 |
| WO2005002586A8 (en) | 2006-02-09 |
| IL172616A0 (en) | 2006-04-10 |
| DE602004028739D1 (de) | 2010-09-30 |
| BRPI0412127A (pt) | 2006-08-15 |
| RU2005141060A (ru) | 2006-07-27 |
| MXPA05013869A (es) | 2006-02-28 |
| JP2007516193A (ja) | 2007-06-21 |
| IS8283A (is) | 2006-02-01 |
| KR20060082037A (ko) | 2006-07-14 |
| AU2004253334A1 (en) | 2005-01-13 |
| WO2005002586A1 (en) | 2005-01-13 |
| ATE477803T1 (de) | 2010-09-15 |
| EP1644005A1 (en) | 2006-04-12 |
| UY28400A1 (es) | 2005-01-31 |
| ES2349091T3 (es) | 2010-12-27 |
| AR045004A1 (es) | 2005-10-12 |
| CN1816339B (zh) | 2010-12-15 |
| CN1816339A (zh) | 2006-08-09 |
| EP1644005B1 (en) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200509944A (en) | Metabolite | |
| US6174878B1 (en) | Topical use of kappa opioid agonists to treat otic pain | |
| US8138169B2 (en) | Combination therapy for bipolar disorder | |
| JP2011520981A5 (https=) | ||
| GR3036422T3 (en) | Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid and of pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization | |
| NZ517659A (en) | Pharmaceutical delivery system for enhanced absorption of hydrophilic therapeutic agents | |
| EP2367554A2 (en) | Bile acid recycling inhibitors for treatment of obesity and diabetes | |
| WO2011075539A2 (en) | Treatment of obesity or diabetes with bile acid sequestrants | |
| WO2016166679A1 (en) | Use of an acetylcholinesterase inhibitor and pharmaceutical compositions containing said inhibitor | |
| AU6528400A (en) | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms | |
| WO2010060742A1 (en) | Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders | |
| GB0201367D0 (en) | Composition | |
| US20060069039A1 (en) | Treatment of dyskinesia | |
| ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
| CN1681512B (zh) | 2,3-苯并二氮杂草在制备治疗与基底神经节相关的运动疾病的药物中的应用 | |
| EP1682157A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia | |
| WO2008069726A1 (en) | Treatment of resistant schizophrenia and other cns disorders by the use of thioxanthenes | |
| IL162391A (en) | Use of darifenacin in the manufacture of medicaments for reducing urgency in dry overactive bladder patients | |
| JP2003516350A (ja) | （ｓ）−２−（ベンジルアミノメチル）−２，３，８，９−テトラヒドロ−７ｈ−１，４−ジオキシノ（２，３）ｅインドール−８−オンと神経遮断薬との組合せ | |
| ES2250703T3 (es) | Pramipexol como anticonvulsivo. | |
| EP1815854A1 (en) | Treatment of dyskenesia | |
| Folnegović-Šmalc et al. | Ziprasidone in treatment of patients with schizophrenia | |
| Hamner et al. | Quetiapine treatment in post-traumatic stress disorder: a preliminary open trial of add-on therapy | |
| Walbert | end-stage neurological | |
| HK1128593B (en) | A composition suitable for ophthalmic administration |